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Resumo 
 
Introdução: O interesse demonstrado em aceleradores lineares sem flattening filter 
justifica o estudo da qualidade das planimetrias de Radioterapia com Intensidade 
Modulada (IMRT) e Arco-terapia Volumétrica Modulada (VMAT) efectuadas com e sem 
flattening filter (FF). 
Materiais e métodos: Foram seleccionados três casos de cancro de próstata em 
estadio inicial. Efectuaram-se planimetrias de IMRT e VMAT com e sem FF, baseado 
no formalismo de Pareto optimal fronts. Sistematicamente variando a função de custo 
de um órgão de risco, diferentes distribuições de dose foram calculadas.  
Para comparar as diferentes técnicas, Pareto optimal fronts foram analisadas. As 
Pareto optimal fronts são determinadas através da representação gráfica de 
determinados valores da distribuição de dose para o PTV e para o órgão de risco. 
Comparando os resultados para cada técnica ajudará a decidir qual a melhor técnica 
para aquele paciente. 
Resultados: Foram efectuadas planimetrias para IMRT e VMAT com e sem flattening 
filter com qualidade similar. No caso 1 e 2, as Pareto optimal fronts diferem 
significativamente para IMRT e VMAT, apresentando melhores resultados para IMRT 
sem FF. No caso do terceiro paciente as Pareto optimal fronts encontram-se 
sobrepostas. O tempo de administração do tratamento para IMRT sem FF foi reduzido 
em 24% e diminuiu de uma forma mais acentuada para as técnicas de VMAT. 
Registou-se um aumento de 9-15% no número de unidades monitor para feixes não 
planares. A análise gama dos planos de IMRT e VMAT revelou pequenas diferenças 
na exactidão do cálculo com e sem FF. 
Conclusão: Os resultados mostraram que é possível desenvolver planos clinicamente 
aceitáveis para IMRT e VMAT, com e sem FF. O conceito de  Pareto optimal fronts 
revelou-se um método eficaz para comparar diferentes métodos e diferentes técnicas 
avançadas de Radioterapia. 
Palavras Chave: Flattening filter, Cancro da Prostata, IMRT, VMAT, Pareto Optimal 
Fronts. 
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Abstract 
 
Purpose: The interest of linear accelerators operating without flattening filter (FF) has 
been increasing in the last few years. For this reason the study of the treatment plan 
quality delivered with and without FF (FFF) is the aim of this project.  
Materials and methods: For this study three early stage prostate cancer cases were 
selected. A treatment planning study based on the concept of Pareto optimal fronts, 
which is considered to provide a more scientific approach, was performed. Several 
plans were made for Intensity Modulated Radiotherapy (IMRT) and Volumetric 
Modulated Arc Therapy (VMAT) with and without FF. By systematically varying the 
EUD maximum of a specific OAR, different dose distributions have been calculated. 
Pareto optimal fronts to compare the two delivery techniques were evaluated. The 
Pareto fronts were determined by plotting presentable values of the dose distribution of 
the planning target volume (PTV) and the organs at risk (OAR). Comparing the fronts 
of each delivery technique will help to decide whether one technique is superior to the 
other.  
Results: Plans with similar plan quality were generated for IMRT and VMAT with 
flattened and unflattened beams. For the case 1 and 2 the Pareto optimal fronts 
differed significantly for IMRT and VMAT, in favor for IMRT. For the third patient, the 
fronts laid virtually on top of each other. The number of MUs was 9-15% higher for 
unflattened beams. By the use of FFF the treatment time was reduced by 24% for 
IMRT FFF and decreased even further for both VMAT techniques. The γ index 
evaluation of the IMRT and VMAT plans showed little difference in calculation accuracy 
in FFF mode compared with the regular beam. 
Conclusion: The results showed that is possible to develop clinically acceptable plans 
for IMRT and VMAT, with flattened and unflattened beams. The approach of using 
Pareto fronts for different systems is a feasible way to compare different methods 
and techniches for advanced radiotherapy. 
Keywords: Flattening filter, Prostate Cancer, IMRT, VMAT, Pareto optimal fronts.  
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1 Introduction 
 
Medical linear accelerators (Linacs) are usually equipped with flattening filters1 to 
compensate for the non-uniform energy fluence distribution of the photons generated in 
the target. 
Recent studies have shown various advantages of Linacs operated without flattening 
filters2-9. One advantage is an increased dose rate, which is beneficial for the patient 
due to a reduction of treatment time10. Furthermore, the removal of the flattening filter 
(FF) leads to a reduction of head scatter, leaf transmission and leakage radiation.11,12 
These properties result in a reduction of the patients' exposure to peripheral dose at 
large distances from the edges of the treatment field. 
Due to the conical shape of flattening filter a decrease of the average energy of the 
photon beam with increasing distance from the central axis can be observed.13 Since 
this so called off-axis softening is less pronounced when the flattening filter is removed 
similar or even higher dose calculation accuracy can be expected from unflattened 
beams. 
Vassiliev et al.3 have shown that it is possible to generate IMRT treatment plans for 
flattened an unflattened beams which are dosimetrically similar. For the unflattened 
plans, however, a reduction of the beam-on time and monitor units (MUs) was 
observed.3,6 While current sequencing algorithms are not customized for non-uniform 
beams and therefore lead to a high number of segments, Kim et al.14 developed an 
algorithm which is able to reduce the number of segments significantly for treatment 
plans with unflattened beams. 
The aim of this thesis is to determine the feasibility of developing clinically acceptable 
treatment plans using unflattened beams, compare them with typical plans developed 
with flattened beams, and explore the potential benefits and drawbacks of using 
unflattened as opposed to flattened beams. Two types of treatment plans will be 
investigated: Intensity Modulated Radiotherapy (IMRT) and Volumetric Modulated Arc 
Therapy (VMAT). As sequencing is a vital step in producing treatment plans by inverse 
planning, the ability of the sequencer to handle unflattened beams is of special interest. 
An Elekta Precise® Linac (Elekta AB, Stockholm, Sweden) at the Medical University of 
Vienna (MUW) was modified to deliver flattened and unflattened photon beams. In the 
flattening filter free (FFF) mode of the accelerator a copper disk is rotated into the 
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beam line instead of the flattening filter to ensure beam stability.13 The Linac is 
equipped with multileaf collimators (MLC) of MLCi type (40 leaf pairs). Basic beam data 
was acquired and implemented into MonacoTM (Elekta CMS Software, St. Louis, MO). 
The initial step of this study is to determine whether the Treatment Planning System 
(TPS) MonacoTM is able to create clinical acceptable plans for IMRT and VMAT with 
and without FF. 
Three prostate cancer patients previously treated with IMRT at the MUW were 
selected.  One plan per investigated treatment modality for each patient was produced. 
Their characteristics are determined by analyzing the dose-volume-histograms (DVHs) 
of the planning target volume (PTV) and the organs at risk (OARs). Certain values, e.g. 
target-coverage, -conformity and –homogeneity, in the PTV, as well as maximum dose 
in the OARs, are derived from the DVHs. 
By systematically varying the serial cost function of the rectum, different dose 
distributions were calculated. Pareto optimal fronts were created. Comparing the fronts 
of each delivery technique will help to decide whether one technique is superior to the 
other. 
The treatment time (T) was recorded and evaluated by delivering the four initial plans 
of each patient using Elekta Precise® Linac (Elekta AB, Stockholm, Sweden), modified 
for the application of FFF beams. 
Finally, dosimetric accuracy of IMRT and VMAT plans with and without flattening filter 
have been assessed by measurements with a 2D detector array Delta4TM (ScandiDos, 
Upsala, Sweden), which also allows a quasi-3D dose acquisition. The acquired data 
was analyzed by gamma index analyses as proposed by Stock et al.15 
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This thesis consists of 6 chapters.  
After the introduction given in Chapter 1, in Chapter 2, the basic fundamentals of this 
project are explained. This includes the Linear Accelerator, the flattening filter, 
quantities that were used, the modulated techniques, Monte Carlo methods, equivalent 
uniform dose formalism and the Pareto Optimality concept. 
Chapter 3 describes the background and the motivation of this work, the 
characterization of the linear accelerator, the beam properties of flattening filter free, 
the IMRT and VMAT techniques, the Monte Carlo Algorithm and the radiobiological 
models. 
In chapter 4 the materials and methods applied in this project are fully described, as 
the clinical cases selected, the planning process, the plan evaluation, the Pareto 
optimal fronts creation and the plan measurements. 
In chapter 5 the summary of the results obtained from the project are described and 
discussed: the treatment plans produced for the three patients are presented. The 
Pareto optimal fronts generated for each patient are shown, and based on that fronts 
the IMRT and VMAT techniques with and without flattening filter are compared. The 
time required to deliver the initial plans of each patient is listed and compared. The 
initial plans were measured and the response of the dosimetry equipment was 
compared with the calculated dose matrices by gamma evaluation.  
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2 Fundamental concepts 
 
2.1 Medical linear accelerator 
Medical linear accelerator (Linac) is an equipment that uses high-frequency 
electromagnetic waves to accelerate charged particles, such as electrons, to high 
energies trough a linear tube. These electrons can be extracted from the unit and used 
for the treatment of shallow lesions, or they can be directed to a target to produce high-
energy x-rays for treatment of deep-seated tumors.16 
 
2.2 Flattening Filter 
Flattening filter, usually with a conical shape, are made of medium and/or high Z 
materials and are shaped to produce a field of uniform intensity at a specified depth.17 
 
2.3 Absorbed dose 
The absorbed dose is defined as the amount of energy deposited in a medium by 
ionizing radiation per unit mass.18 
Formally, absorbed dose at a point is defined by the ICRU as  
  
  
  
 
(eq. 1) 
where ΔE is the mean energy transferred by the radiation to a mass Δm.  
The SI unit of absorbed dose is gray (Gy) and is defined as the absorption of 1 J of 
energy per kilogram of medium. 
 
2.4 Dose Rate 
Dose Rate is the rate of energy absorption per unit mass in a defined point.19 In SI 
units, dose rates may be expressed as Gy/s, mGy/h, etc., and because the Gy is such 
a large unit compared to many common circumstances, the unit Gy/h is often used. 
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2.5 Photon Fluence 
 
The photon fluence Φ is defined as the quotient dN by dA,20 where dN is the number of 
photons that enter in an imaginary sphere of cross-sectional area dA: 
  
  
  
 
(eq. 2) 
The unit of photon fluence Φ is cm–2. 
 
2.6 Output factor in air 
The in-air output ratio, Sc, is defined as the ratio of primary collision water kerma in 
free-space, Kp, per monitor unit between an arbitrary collimator setting and the 
reference collimator setting at the same location.21 
Output factor in air is most commonly called collimator scatter factor or head scatter 
factor. Measurements and analytical studies have shown that there are multiple 
components for output factor in air, in particular, photon head-scatter inside accelerator 
head, x-ray source obscuring effect, and monitor backscatter effect. Various sources of 
head-scatter, which include the flattening filter (and a wedge, if used), have been 
characterized. 
 
2.7 Intensity Modulated Radiation Therapy 
IMRT is the delivery of radiation to the patient via fields that have non-uniform radiation 
fluence.22 It is a sophisticated type of three-dimensional conformal radiotherapy that 
assigns non-uniform intensities to a tiny subdivision of beams called beamlets. The 
ability to optimally manipulate the intensities of individual rays within each beam leads 
to greatly increased control over the overall radiation fluence. 
 
2.8 Volumetric modulated arc therapy 
Volumetric modulated arc therapy is a technique that delivers a precisely sculptured 3D 
dose distribution with a single 360-degree rotation of the linear accelerator gantry. This 
is possible by a treatment planning algorithm that simultaneously changes three 
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parameters during treatment: (1) rotation speed of the gantry, (2) shape of the 
treatment aperture using the movement of multileaf collimator and (3) delivery dose 
rate.23 
 
2.9 Monte Carlo method 
The Monte Carlo (MC) method is a stochastic method for solving complex equations 
providing approximate solutions by performing statistical sampling experiments on a 
computer. They are based on the use of pseudo random numbers and probability 
statistics to investigate problems.24, 
These methods derive their collective name from the fact that Monte Carlo, the capital 
of Monaco, has many casinos and casino roulette wheels are a good example of a 
random number generator. 25,26 
The Monte Carlo simulation techniques have formally existed since the early 1940s, 
where it had applications in research into nuclear fusion. Nowadays MC methods are 
widely used to solve complex physical, economical and mathematical problems, to 
regulate the flow of traffic, etc.  
In particle transport the Monte Carlo technique is used to simulate a huge number of 
histories of individual photons and electrons including all daughter particles. Probability 
distributions are randomly sampled using transport data to determine the outcome at 
each step of its life.27 
 
2.10 Equivalent Uniform Dose  
The concept of Equivalent Uniform dose (EUD) for tumors was introduced by 
Niemierko28 originally as the biologically equivalent dose. For any dose distribution, the 
corresponding EUD is the dose in Gy, which, when distributed uniformly across the 
target volume, causes the survival of the same number of clonogens. Later, Niemierko 
extended the EUD concept to apply to normal tissues as well. 
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2.11  Pareto optimality 
The Italian economist Vilfredo Pareto introduced the mathematical concept of Pareto 
optimality, a concept that formalizes the trade-off between a given set of mutually 
contradicting objectives.29,30 
A solution is said to be Pareto optimal when it is not possible to improve one objective 
without deteriorating at least one of the others. A Pareto front is constituted by the 
Pareto optimal solutions (see figure 1). This concept can be used as an optimization 
method, but also as an analytical instrument. 
 
 
Figure 2.1 The Pareto concept for a given optimization problem. With two mutually contradicting 
objectives an infinite number of solutions exist. All Pareto optimal solutions build the Pareto 
front.
31
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3 Background 
 
In external radiotherapy, the x-ray treatment fields are usually delivered by a medical 
linear accelerator. Various types of modern linear accelerator designs are available.  
The Linac can be used in two distinct operation modes: electron mode and photon 
mode. In electron mode primary electrons are used for treatment, in photon mode, 
photons are produced for treatment.32 
In photon mode primary electrons are directed onto a bremsstrahlung target. This 
target creates bremsstrahlung radiation with a thin tungsten disk of approximately 1 
mm height. 
The high-energy x-ray beam produced in the target is defined by a primary collimating 
system and is intercepted by a flattening filter and multiple ion chambers before exiting 
the head of the machine through a secondary collimator consisting of movable 
leaves.33 
The flattening filter is placed in the x-ray beam to reduce the intensity of the forward 
peaked dose in the center of the field.17 
 
 
Figure 3.1. Schematic cross section of the treatment head of an Elekta Linac and typical dose 
profile without FF.
35
 
Metcalfe et al36 referred that to be useful for conventional radiotherapy the treatment 
fields have to be uniform. This ‘beam flatness’ was achieved by the introduction of a 
flattening filter in the beam line. 
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With the advent of IMRT and other modulated techniques, the original photon fluence 
will be modified by the movement of the MLC, therefore questions the need for a FF.37 
 
3.1 Beam properties of unflattened beams 
There are several studies that summarize the dosimetric properties of unflattened 
photon beams based on Monte Carlo (MC) simulations or dosimetric 
measurements.35,38-48 These studies have shown many advantages in removing 
flattening filter from the beam line.  Recently, Kragl et al45, Cashmore4 and Dalaryd et 
al48 have published experimental data on the dosimetric characteristics of unflattened 
beams.  
The main advantages of removing the flattening filter are an increased dose rate4,39,45, 
which is beneficial for the patient due to a reduction of treatment time11, reduced 
scatter4,42,45, reduced leaf transmission and leakage radiation4, reduced out of field 
doses48 and reduction in the dose from neutrons to the patient and to radiation 
personnel2,49,50.  
 
 
Figure 3.2. Comparison of Monte-Carlo simulated X-ray spectra on the central beam axis and 
the field edge of a) flattened and b) unflattened 10 MV beams provided by an Elekta Linac.
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Figure 3.2 shows unnormalized Monte-Carlo simulated X-ray spectrum of flattened and 
unflattened 10 MV beams provided by an Elekta Linac. From Figure 3.2 two effects 
become apparent. Firstly, the photon energy fluence for FFF beams is increased and 
results in an increased dose per pulse47, as mentioned above. Secondly, the off-axis 
spectral dependence is very small, based on this we can expect a similar or even 
higher dose calculation accuracy for unflattened beams. 
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3.2 IMRT/VMAT 
IMRT is the delivery of radiation to the patient via fields that have non-uniform radiation 
fluence.37  
 
Figure 3.3. An example of a 9 field IMRT technique dose distributions, where the grey levels 
indicate the intensity values of the beamlets.
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Several papers have addressed this issue of unflattened beams for IMRT.3,8-10 In 
theory, the flattening filter could be removed and the required fluence distribution can 
be achieved by modulating the unflattened non-uniform fluence distribution directly.4,10 
The current method of optimizing the photon beam fluence using MLCs is realized by 
manipulating the uniform photon beam fluence by creating areas of high and low 
intensity according to the requirements of the plan. The photon beam fluence is divided 
into elemental beam areas that are assigned a weight which is directly proportional to 
the MU that will be delivered through this area (segment). The weights of each 
elemental area are then manipulated (increased or decreased) with respect to its 
contribution to the planning dose criteria. The optimized beam intensity is then 
delivered using the MLC. Several beam segments of different MUs are used in each 
case to deliver the planned photon fluence. Since the photon beam fluence is based on 
the optimization of elemental areas, it is not conceptually necessary to start with a 
uniform beam8. 
The reduction of treatment head leakage and scattered radiation for FFF beams is 
advantageous for IMRT.17 Although the increased dose rate of FFF beams is another 
potential advantage for IMRT, the MU delivery is only one contribution to the total time 
for a treatment fraction. The reduction of beam-on time may be discounted by the 
increase of leaf-travel time and (or) verification-and-recording time.10 
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For segmental or step-and-shoot IMRT, the number of segments and, consequently, 
the leaf travel time has a large impact on treatment delivery efficiency, especially for 
standard fractionation schemes with about 2 Gy per fraction. When using the same 
objectives for treatment plan optimization, it cannot be a priori assumed that the 
number of segments is identical for IMRT plans with and without FF.17 
While current sequencing algorithms are not customized for non-uniform beams and 
therefore lead to a high number of segments, Kim et al.52 developed an algorithm which 
is able to reduce the number of segments significantly for treatment plans with 
unflattened beams. 
Stathakis et al8 reported a significant reduction in the number of MUs for several IMRT 
indications. However, the Linac was calibrated to provide doses of 2 cGy and more 
than 3 cGy per MU for 6 and 18 MV beams without a FF. When using a standard Linac 
calibration of 1 cGy/MU, the total number of MU will probably be very similar for 
flattened and unflattened beams. For sliding window IMRT and rotational IMRT, the 
current leaf speed around 3 cm per second has a natural limit for the dose rate.17 
During the last years rotational IMRT or VMAT has become a promising and 
commercially available treatment option.23,54,55  
VMAT is a completely dynamic technique performed by means of one or more gantry 
arcs: while the gantry is rotating beam aperture is changed continuously, the dose rate 
is varied and collimator rotation is also enabled. Treating the patients with the widest 
number of beam orientations may potentially ensure high dose conformity and sparing 
of normal tissue reducing simultaneously the number of MU and delivery times with 
respect to other established modulating techniques.55  
Unflattened beams provide a larger dose rate range, which might offer advantages in 
the optimization of rotational IMRT. Finally, unflattened beams might be more stable 
during delivery of static or rotational IMRT since they are less susceptible to changes in 
beam steering.4,17,47  
 
3.3 Treatment Planning System 
Current cancer treatment techniques as IMRT and VMAT allow precise dose deposition 
in the target volume and an improved spare of the normal tissue. A good plan and 
accurate dose calculation is essential to assure the efficacy of these techniques.  
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3.3.1 Dose Calculation Algorithms 
For many years Monte Carlo is a commonly known dose calculation algorithm for 
researchers in the field of radiotherapy, since it represents the most accurate method 
for absorbed dose calculations.56 However, the implementation of Monte Carlo 
calculations in clinical use are time consuming and need high performance computing 
to be time efficient and practical. To reduce the calculation times Fippel et al.57 
developed a fast Monte Carlo algorithm for photon beams called XVMC. 
The implementation of this algorithm is important to solve the central problem of IMRT, 
the modelling of radiation transport through complex geometries. Field geometries are 
much more irregular and smaller in IMRT than in conventional radiotherapy. With 
smaller field sizes, the modelling of scatter from the collimators or compensator filters 
becomes more important. These effects can be modeled precisely with Monte Carlo 
methods.58 The simulation of radiation transport with these methods imitates the 
physical processes at the price of significantly longer computation times. Nevertheless, 
Monte Carlo dose computation was included into the algorithm with clinically 
acceptable computation times.59 
The dose calculation algorithms implemented in the treatment planning system 
(TPS) Monaco
TM
 (Elekta CMS Software, St. Louis, MO) are Pencil kernels and Monte 
Carlo. Figure 3.4 illustrates exemplarily that MonacoTM with multi-source models and 
advanced dose calculation algorithms can be commissioned for FFF beams. 
 
Figure 3.4. Comparison of measured and MC-calculated profiles of a) flattened and b) 
unflattened 10 MV beams obtained during commissioning of the TPS Monaco
TM
, for a 15 x 15 
cm
2
 field at 10 cm depth. Courtesy of Elekta. 
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3.3.2 Optimization incorporating biological information 
The goal of radiation therapy is to maximize tumor response while minimizing side 
effects in normal tissues. Optimization of treatment plans has traditionally been 
performed using surrogate approaches, such as maximization of tumor dose and 
minimization of dose to organs at risk.60 
Many studies demonstrated that incorporating biologically based objective function, 
which takes patient and tumor/organ-specific biological features, into inverse treatment 
planning algorithms can substantially improve the quality of the plan generated leading 
to improve sparing of organs at risk with comparable target coverage.60-65 
A number of mathematical models have been developed over the years to better 
describe the biological effect of radiation, which include tumor control probability 
(TCP),66 normal tissue complication probability (NTCP),67 equivalent uniform dose 
(EUD)28 and the probability of uncomplicated tumor control (P+).68,69  
The optimization based on radiobiological models became even more important with 
the advent of IMRT and inverse treatment planning,70,71 although the progress was 
hampered by limitations of plan optimization based on purely biological indices.72  
An equivalent uniform dose concept28,73 has gained considerable popularity in the area 
of biologically based treatment planning because it incorporates information about the 
organ functional architecture (serial or parallel), lies in a more familiar to clinicians 
dose-volume domain, and possesses desired mathematical properties.61,74 At the 
moment, does not rely on too many parameters with large uncertainties, such is the 
case with TCP and NTCP. 
The concept of Equivalent Uniform Dose (EUD) for tumors was introduced by 
Niemierko28 originally as the biologically equivalent dose that, if given uniformly, would 
lead to the same cell kill in the tumor volume as the actual non-uniform dose 
distribution. Later, Niemierko73 extended the EUD concept to apply for both tumors and 
normal tissues. 
    (
 
 
∑  
 
 
)
 
 
 
(eq. 3) 
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In this expression, N is the number of voxels in the anatomic structure of interest, Di is 
the dose in the i’th voxel, and a is the tumor or normal tissue-specific parameter that 
describes the dose–volume effect. This formulation of EUD is based on the power law 
dependence of the response of a complex biologic system to a stimulus. This type of 
relationship has been observed in many biologic phenomena since the mid-19th 
century and has also been incorporated into the EUD concept. 
EUD described in Eq. 1 is the general mean of the non-uniform dose distribution. 
According to the mathematical properties of the function75 for a=∞ the EUD is equal to 
the maximum dose, and for a= -∞, the EUD is equal to the minimum dose. Tumors 
generally have large negative values of a, whereas serial critical structures (e.g., spinal 
cord and rectum) have large positive values and parallel critical structures that exhibit a 
large dose-volume effect (e.g., liver, parotids, and lungs) have small positive values. 
The simplicity of EUD is due in part to the fact that the same formalism is used for both 
tumors and normal tissues and in part that the desired EUD values can be easily 
related to conventionally required dose or dose–volume limits.  
Many investigators have demonstrated that incorporating EUD based or hybrid, EUD 
and dose-based, cost functions into inverse treatment planning algorithms often leads 
to improved sparing of OARs with comparable target coverage.61,76-79 
The biological cost functions implemented in the MonacoTM are based on a formalism 
developed at the University of Tübingen,59,80 which is comprised of sparsely 
parameterized expressions to convert three-dimensional dose distributions to either an 
EUD for the Poisson cell kill model and Serial complication model or a fraction of organ 
damaged for the Parallel complication model. These biological indices are then 
included in the overall objective score for plan optimization. 
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3.4 Motivation 
 
The interest of a linear accelerator operating without flattening filter has been 
increasing in the last few years. The flattening filter (FF) was considered as an 
essential component of almost all linear accelerators, acting to produce a flat beam 
from the forward-peaked photon fluence produced at the target.  
With the introduction of IMRT, the initial flat beam is no longer needed since the 
required fluence distributions can be achieved by modulating the unflattened non-
uniform fluence distribution directly. 
Besides that, recent studies have reported various advantages of removing the 
flattening filter. The major advantages are an increased dose rate3, reduced scatter, 
reduced leakage and reduced out-of-field doses.  
The benefits of unflattened beams are already reported in the community however, 
before implementing these techniques without FF in a clinical environment, treatment 
planning studies must be done, in order to evaluate the ability of the TPS to handle 
unflattened beams.  
The motivation for this work is related to the possibility to perform IMRT/VMAT 
treatments without flattening filter reducing the peripheral doses in the patient and 
reducing the treatment time. 
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4 Materials and Methods 
4.1 Linear Accelerator 
All measurements in the framework of this thesis were performed with an Elekta 
Precise® Linac (Elekta AB, Stockholm, Sweden) at the Medical University of Vienna 
(MUW) that was modified to deliver flattened and unflattened photon beams. In the FFF 
mode of the accelerator a 6 mm thick copper disk (fig. 4.1) is rotated into the beam line 
instead of the flattening filter to ensure beam stability. The beam servo control and 
feedback system to electron gun, which is driven by the monitor chamber in the 
particular Linac, could thus be operated in a quasi-clinical mode. To prevent 
unflattened beams from accidental clinical use the Linac Control System (LCS) for FFF 
beams was running on a separate hard drive. 
The Linac is equipped with an MLC consisting of 40 leaf pairs (isocentric leaf width 1 
cm) and backup-jaws allowing a maximum field size of 40 x 40 cm2.  
 
Figure 4.1. The cooper filter used in FFF mode a) and the carousel of an Elekta Linac b). 
Courtesy of Elekta. 
The calibration of the linear accelerator for the 10 MV energy was performed to have 1 
cGy/monitor unit (MU) for a 10 x 10 cm2 field at a depth of 10 cm. 
 
4.2  Treatment planning system 
Treatment plans were performed with the Treatment Planning System CMS MonacoTM 
version 2.04 (Elekta CMS Software, St. Louis, MO) – non-clinical version.  
MonacoTM is one of the first commercial IMRT treatment planning systems based on 
biological optimization. In addition to physical cost functions, such as dose-volume 
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histogram (DVH) constraints and maximum dose, MonacoTM offers three biological cost 
functions.  
MonacoTM 2.04 optimizes the dose distribution in the PTV and OARs by assigning one 
or more cost functions to each structure and minimizing these cost functions. 
A summary of cost functions used to design the Monaco plans is shown in Table 4.1. 
For each cost function assigned to a structure, the TPS computes an index that reflects 
presumed biological response of the structure to a currently attained dose distribution. 
This index is referred as isoeffect, and depending on the type of cost function may be 
expressed either in units of dose or as a percentage of organ damaged. 
Following each optimization step, calculated isoeffects for all cost functions were 
compared with user-specified values referred to as isoconstraints. Optimization is 
stopped when no additional dose can be given to targets without isoeffects exceeding 
their corresponding isoconstraints. 
Table 4.1 Cost functions used to design Monaco plans81 
Applicability Model name Parameters and 
isoconstraints 
Description 
Biological cost functions 
Targets Target EUD 
Cell sensitivity (0.1–1.0) 
EUD prescription (Gy or 
cGy) 
Mandatory cost 
function for targets; no 
penalty for hot spots 
OARs Serial 
Power law exponent (≥1) 
Equivalent uniform dose 
(Gy or cGy) 
Penalizes for hot spots 
OARs Parallel 
Reference dose (Gy or cGy) 
Power law exponent (≥1) 
Mean organ damage (%) 
Effective for reducing 
mean organ dose 
Physical cost functions 
Targets or 
OARs 
Quadratic 
overdose 
penalty 
Maximum dose (Gy or cGy) 
Root mean square dose 
excess (Gy or cGy) 
Penalizes for hot spots 
with some leniency 
Targets or 
OARs 
Maximum dose Maximum dose (Gy or cGy) Penalizes for hot spots 
with zero leniency 
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OARs 
Overdose-
volume 
DVH 
Threshold dose (Gy or cGy) Forces a DVH through 
or below a single point 
 
4.2.1 Optimization Process  
MonacoTM employs a two-stage process for the optimization of dose distributions. The 
TPS optimizes the dose distribution in the PTV and OARs by assigning one or more 
cost functions to each structure, in agreement with the dose prescriptions, and 
minimizing these cost functions58. 
In the first stage the optimized fluence maps are created and the dose distribution is 
calculated with a finite size pencil beam algorithm.82 In the second stage, the beam 
segmentation is optimized. The sequencer tries to rebuild these fluence maps by 
optimizing the number and shape of the segments for each beam. This is done by 
varying the shape of the segments, updating the dose distribution by Monte Carlo 
simulation and recalculating the optimization problem59. This process is repeated till an 
improvement of the optimization can be no longer observed.81  
The plans were made for delivery on an Elekta Precise® linac (Elekta AB, Stockholm, 
Sweden) which use the Elekta MLCi beam shaping. 
4.3 Dosimetric equipment 
The dosimetric accuracy of IMRT and VMAT plans with and without flattening filter 
have been assessed by measurements with a 2D detector array (Delta 4 by 
ScandiDos), which also allows a quasi-3D dose acquisition. The acquired data was 
analyzed by gamma index analyses as proposed by Stock et al.15 
4.3.1 Delta 4 
The Delta 4 phantom (Scandidos, Uppsala, Sweden) consists of a crossed array inside 
a 22 cm diameter cylindrical polymethyl methacrylate (PMMA) phantom, and 
associated computer software allows the user to compare the measured dose 
distribution for a complete treatment plan with the dose distribution predicted by the 
treatment planning system.83 
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There are a total of 1069 p-type cylindrical silicone diodes, which active volume is 1 
mm in diameter and 0.05 mm thick. The nominal detector sensitivity is 5 nC/Gy. 
Temperature sensitivity variation is reported by the manufacturer as 0.32%/°C. 
The detectors are arranged in rectangular patterns on two orthogonal planes. The first 
plane is called the “main board” and has the measurement area of 20 × 20 cm2. The 
other plane is made up of two halves (“wings”), covering 20 × 10 cm2 each, which 
allows easy assembly of the detector boards in the orthogonal position in the phantom. 
The central line of detectors on the main board coincides with the long axis of the 
phantom. 
The detectors are spaced 0.5 cm apart in the central 6 × 6 cm2 area, and 1 cm apart 
elsewhere. Rather than being angled ± 45º, the detector boards are separated from the 
vertical by + 50° (main board) and - 40º (wings). The phantom can be positioned on the 
couch with the electrometers facing either away from the gantry (Fig. 4.2), or towards 
the gantry (reversed orientation). 
 
 
Figure 4.2. The Delta4 phantom and associated devices positioned on the Linac couch.
84
 
 
The device records measured dose in relation to the individual accelerator pulses by 
using a trigger signal from the accelerator. The trigger pulse precedes the dose pulse 
by a few microseconds. Readings over several dose pulses are packaged and sent to 
the control PC. This synchronization of the measurement with the accelerator pulse 
improves the signal to noise ratio, and adds the temporal dimension to the data, 
allowing, for example, the association of the dose-packages with individual control 
points (segments) of the IMRT plan. For rotational treatments, gantry angle is 
independently sensed by means of an inclinometer attached to the gantry or 
  
39 
 
accelerator head. This allows the device to identify which control point of a dynamic arc 
delivery is being delivered, so that the measured dose can be associated with this 
control point and the appropriate correction for gantry angle applied.85 
4.3.1.1 Delta 4 calibration 
The Delta 4 phantom needs to be calibrated by the user once a year.83 The unit is 
equipped with a calibration PMMA phantom, to perform the calibration. The relative 
calibration (equalization), establish the basic sensitivity value for each diode detector 
relative to the reference detector, and the absolute dose calibration is performed to 
convert the detector signal in absolute dose values. 
4.3.2 Ionization chamber 
An ionization chamber consists of a gas filled cavity between two conducting 
electrodes. When the gas between the electrodes is ionized, the produced ions and 
dissociated electrons move to the electrodes of the opposite polarity, thus creating 
ionization current. This current can be amplified and measured. There are multiple 
designs of ionization chambers. For dose determination in water, the most common 
types are cylindrical chambers with air as counting gas. They consist of an active 
volume with a central collecting electrode, located in the axis of symmetry. Typically, 
the active volume of an ionization chamber in medical use ranges from 0.1 cm3 to 1 
cm3.86 
An ionization chamber PTW 31003 (Farmer type chamber) with an active volume of 0.6 
cm3 was used for measure the Linac daily output. 
 
4.4 Prostate cases 
For this study three early stage prostate cancer cases were selected from a database 
of patients previously treated with IMRT at the Medical University of Vienna. The 
selection criteria for the cases were: PTV, rectum, bladder, left and right femoral heads 
and normal tissues fully delineated, and an overlapping of the target with the rectum. 
As a result of this overlap it is expected to be a conflict or trade-off in the optimization 
between the overlapping structures. The PTV includes the prostate plus 5mm uniform 
margin. The rectum was filled with a rectum balloon and the bladder of the three 
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selected patients have more than 152 cm3. More details on the cases are given in table 
4.2. 
 
Table 4.2 Case specific information 
 
Prescription 
(Gy)  
Prostate 
(cm
3
) 
PTV  
(cm
3
) 
Rectum 
(cm
3
) 
Prostate 1 78 28 106 119 
Prostate 2 78 73 202 109 
Prostate 3 78 65 185 100 
 
4.5 IMRT/VMAT planning 
In order to evaluate the possibility to create clinical acceptable treatment plans to 
deliver with flattened (FF) and unflattened beams (FFF), treatment plans for IMRT and 
VMAT were produced, for each patient. 
For IMRT the prescription dose was 78Gy in 2Gy fractions to the PTV. A target EUD 
cost function was applied to the target, and a serial cost function has been applied to 
the rectum and to the bladder. A constraint was applied to the normal tissue to prevent 
for non-allowed hot spots. Nine coplanar and non- opposing beams of 10 MV photons 
were used for the IMRT planning with step-and-shoot delivery. The gantry was placed 
at 180º, 220º, 260º, 300º, 340º, 20º, 60º, 100º and 140º.  
For VMAT one full arc of 360º (from -180º to 180º) of 10 MV photons was planned 
without gaps in delivery. The prescription dose was 78Gy in 2Gy fractions to the PTV. 
The same cost functions and OAR dose constraints have been applied. 
In order to create similar plans for IMRT and VMAT the “rule of 3” proposed by Elekta 
have been applied,81 this means that the user should add three (3) to the number of 
static beams that he used to treat this patient. For example, if nine (9) beams were 
used to plan a standard IMRT plan, consider creating 12 sectors (9+3) for VMAT. 360 
deg arc/12sectors = increment of 30. 
In this case 5 beams IMRT plans and a full VMAT arc with 12 sectors were created. In 
order to create similar plans 4 beams were added to the IMRT plans, in total, 9 beams 
have been created for IMRT technique with and without FF. 
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Dose distributions have been calculated using the Monte Carlo algorithm with 3% 
Monte Carlo variance. The calculation grid was 3mm. 
 
4.6 Plan evaluation 
The characteristics of the plan have been determined by analyzing the dose-volume-
histograms (DVHs) of the planning target volume (PTV) and the organs at risk (OARs). 
The treatment plans have been considered as clinically acceptable if 95% of the PTV 
volume receive more than 95% of the prescribed dose and if fulfill the QUANTEC 
recommendations for OAR. For the rectum87: V50<50%, V60<35%, V65<25%, V70<20%, 
and V75<15%. For the bladder
88: V15<80Gy, V25<75Gy, V35<70 Gy and V50<65Gy. 
 
4.7 Pareto Optimal Fronts 
The second step of this study was to determine whether the treatment planning system 
MonacoTM (Elekta Oncology Systems) can be used to obtain Pareto optimal fronts. 
Pareto optimality is a concept of formalizing the trade-off between contradicting 
objectives of a given optimization problem.  
The Pareto concept applies well to the inverse planning process in which more than 
one objective function has to be optimized simultaneously.89,90 
Ottosson et al.31 have shown the feasibility of planning studies using Pareto fronts and 
successfully used it to compare different dose calculation algorithms for different 
photon beam energies.91 
In this study, Pareto fronts were created for prostate cases by varying the EUD 
maximum for the rectum. The plan was rejected when the coverage of PTV was 
compromised. The target coverage is expected to decrease with the decrease of the 
EUD maximum for the rectum. 
The number of plans produced for each patient per treatment modality, is listed in table 
4.3. For the first patient 191 plans were created by systematically varying the EUD 
maximum for the rectum, and for four fix values of EUD maximum of the bladder. After 
to create such a big number of plans, the fronts were created and it was noticed that it 
have a lot of non-Pareto optimal plans. For this reason it was decided to reduce the 
number of plans for the next patients. For the second and the third patients the number 
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of plans was reduced to 76 plans and 75 plans, respectively. As in the first patient the 
plans were created by systematically varying the EUD maximum for the rectum (until 
the plan been rejected) and for two fix values of the EUD maximum of the bladder. 
  
Table 4.3 Number of plans produced for each patient per treatment modality 
 IMRT FF IMRT FFF VMAT FF VMAT FFF 
Patient 1 46 44 50 51 
Patient 2 19 20 19 18 
Patient 3 19 20 18 18 
 
The dose of the most exposed 10% of the rectum (D10%) was used together with the 
volume of the PTV which received less than 95% of the prescribed dose (100%-
V95%PTV/%) to comprise the fronts. Rectum sparing was chosen as an evaluation 
parameter for the prostate cases as it competes with PTV coverage.  
For each patient and technique the DVH’s generated by Monaco were exported and 
imported in MATLAB R2009b (The MathWorks, Inc., Natick, MA, USA) to plot the 
fronts. The fronts were generated and compared for each technique and for each 
patient. The points not contributing to the front were discarded. Comparing the fronts of 
each delivery technique will help to decide whether one technique is superior to the 
other. 
 
4.8 Doses, Segments and Treatment Times 
The near maximum (D2%), near minimum (D98%) and median dose (D50%) were reported 
for the PTV according to ICRU 83 recommendations. Also, the number of monitor units 
(MUs) and segments (Seg) were recorded. 
The treatment time (T) was evaluated by delivering the four initial plans of each patient 
using Elekta Precise® Linac (Elekta AB, Stockholm, Sweden), modified for the 
application of FFF beams. 
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4.9 Conformity Index and Homogeneity Index  
The conformity index (CI) and homogeneity index (HI) were computed to assess the 
quality of the dose distribution. 
The Dose conformity index used in this work was introduced by van’t Riet, et al.92 and 
simultaneously takes into account the irradiation of the target volume and the 
irradiation of healthy tissues, and is defined as: 
    
    
  
 
    
   
 
(eq. 4) 
where TVRI  is the target volume covered by the reference isodose, TV is the  target 
volume, and VRI  is the volume of the reference isodose. 
The first fraction of this equation defines the quality of coverage of the target; the 
second fraction defines the volume of healthy tissue receiving a dose greater than or 
equal to the prescribed reference dose. The CI ranges from 0 to 1, where 1 is the ideal 
value. A value close to 0 indicates either total absence of conformation, i.e., the target 
volume is not irradiated or there is a very large volume of irradiation compared to the 
target volume.93 
Dose homogeneity characterizes the uniformity of dose distribution within the target 
volume. The homogeneity index is defined as: 
   (        )      
 
(eq. 5) 
 
where the D2% is the near maximum dose, the D98% is the near minimum dose and the 
D50 % is the median dose suggested as the normalization value by ICRU 83.94 An HI of 
zero indicates that the dose distribution is almost homogeneous. 
 
4.10 Planning verification 
For QA purposes, the initial plans made for each patient and for each technique with 
and without FF were recalculated on a CT scan of the phantom. The plans were 
recalculated on the artificial CT scan of the Delta4 keeping all other parameters 
identical to the patient plan, and placing the isocenter in the center of the cylindrical 
  
44 
 
Delta4 phantom geometry. Dose distributions have been calculated using the Monte 
Carlo algorithm with 1% Monte Carlo variance. The calculation grid was 2mm. 
The DICOM RT objects, such as RT Dose (calculated in the phantom), RT Dose per 
beam and RT plan (beam arrangements) were exported to the ScandiDos software 
(Scandidos, Uppsala, Sweden). 
First, the output of the accelerator was measured using an ionization chamber and the 
Delta4 daily output correction factor was set to compensate for any deviation from 
calibration conditions. 
The Delta4 and associated devices were positioned and aligned in the Linac couch. 
The DICOM RT objects were imported in the ScandiDos software. The IMRT and the 
VMAT plans with FF were then delivered to the Delta4 phantom. Without changing any 
setup, the hard drive of the LCS was changed to allow for the delivery of FFF beams. 
The IMRT and the VMAT plans without FF were then delivered to the Delta4 phantom. 
 In measurement mode, raw readings were converted to dose by applying a number of 
correction factors. The response of the dosimetry equipment was compared with the 
calculated dose matrices by gamma evaluation. 
 
4.11 Gamma Index 
The quantitative comparison of two-dimensional dose distributions, e.g. calculated 
versus measured has become a key issue in multi-dimensional dosimetry with the 
implementation of IMRT.51 
In 1998 Low et al.95 proposed the γ evaluation method for the quantitative evaluation of 
two-dimensional dose distributions. This concept combines a dose difference criterion 
with a distance-to-agreement (DTA) criterion for each point of interest. The DTA 
specifies the distance from one measured point to the closest calculated point of the 
same dose. The criterion is used because of the fact that a spatial difference in a high 
gradient area can correspond to a large dose difference. 
The γ index evaluation method has the advantage of being able to determine 
calculation accuracy for plans with a complex gradient composition, e.g. IMRT and 
VMAT plans, as it simultaneously takes into account both dose differences and DTA 
without distinguishing between areas of different gradient size.96 
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For the present work, the criteria of a combination of three parameters proposed by 
Stock et al.15 given in Table 4.4 were used. Based on the results of their work with 10 
IMRT hybrid plans verified with film and polystyrene phantom, they developed a 
decision filter looking at γmean values, the average number of pixels with γ>1, and the 
maximum γ value expressed as the 1st percentile (γ1%). 
Such a type of recommendation depends on the chosen set of gamma evaluation 
criteria, in this case a dose difference, relative to dose maximum, of 3% and 3mm DTA 
criteria was used, the same that is applied clinically at the Medical University of Vienna. 
The same criteria were used in the γ evaluation for both flattened and unflattened 
treatment plans. 
 
Table 4.4 Criteria for acceptability of gamma evaluations of pre-treatment verification of IMRT 
beams.
15
 
Approach Average gamma 
Maximum 
gamma 
%> 1 
Acceptable < 0.5 < 1.5 0 – 5% 
Need further 
evaluation 
0.5 – 0.6 1.5 – 2.0 5 – 10% 
Not acceptable > 0.6 > 2.0 > 10% 
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5 Results and Discussion 
In this chapter, a summary of the major results is presented and discussed. 
 
5.1 Clinical Acceptable Plans 
For each patient a set of clinically acceptable plans with similar DVHs was created for 
all modalities, as shown in figure 5.1.  
IMRT plans and VMAT plans as similar OAR DVHs and similar PTV DVHs achieved 
during treatment planning. The PTV as the same median dose, which is a prerequisite 
to achieve similar and thus comparable clinical conditions with respect to tumor control. 
 
 
 
Figure 5.1. Initial DVHs generated for the three prostate cases, for IMRT using FF (red) and 
FFF beams (blue) and for VMAT using FF (green) and FFF beams (black). 
 
During inverse planning, sequencing is performed by the TPS and the sequencer was 
able to deal with unflattened beams. In order to achieve comparable IMRT treatment 
plans the segment shapes and number of segments were different for IMRT plans with 
flattened and unflattened beams; this will be discussed later on.  
a) 
c) 
b) 
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For the three prostate cases, results of the dose metrics according with ICRU 83 are 
summarized in Table 5.1. The Dnear-min=D98%, Dnear-max=D2% and D50% (median) are 
indicated for the PTV. The V95% is the volume (%) that receives at least 95% of the 
prescribed dose is also reported in Table 5.1. 
 
Table 5.1 The dose-volume metrics presented as mean values ± 1SD 
 
The use of multiple dose-volume constraints (e.g., Dmedian, D98%, D95%, D2%) for each 
defined volume leads to more precision in the planning aims and is therefore 
recommended by ICRU 83. 
For the first patient the VMAT plans, on average, delivered slightly a higher dose to the 
PTV than did the IMRT plans, this is characterized by a higher near maximum dose 
D2%. For the second and third patient the IMRT FFF, deliver slightly a higher dose, 
compared to the other techniques. 
 Patient 1 
 IMRT FF IMRT FFF VMAT FF VMAT FFF 
D98%(PTV) Gy 74.3 ± 1.2 74.1 ± 0.9 72.6 ± 1.0 72.7 ± 0.9 
D2%(PTV) Gy 82.1 ± 0.1 82.9 ± 0.1 83.1 ± 0.1 83.2 ± 0.1 
D50%(PTV) Gy 79.7 ± 0.2 79.9 ± 0.2 79.8 ± 0.5 79.9 ± 0.3 
V95%(PTV) % 97.8 ± 2.2 97.9 ± 1.5 95.1 ± 2.5 95.6 ± 1.9 
 Patient 2 
 IMRT FF IMRT FFF VMAT FF VMAT FFF 
D98%(PTV) Gy 73.2 ± 1.4 72.3 ± 1.1 72.3 ± 1.0 72.3 ± 0.8 
D2%(PTV) Gy 82.4 ± 0.0 83.3 ± 0.0 83.1 ± 0.1 83.0 ± 0.0 
D50%(PTV) Gy 79.9 ± 0.4 79.6 ± 0.4 79.9 ± 0.5 79.9 ± 0.4 
V95%(PTV) % 96.4 ± 2.3 94.6 ± 2.5 95.3 ± 2.1 95.3 ± 2.0 
 Patient 3 
 IMRT FF IMRT FFF VMAT FF VMAT FFF 
D98%(PTV) Gy 72.1 ± 1.6 71.9 ± 1.5 72.9 ± 1.4 72.8 ± 1.2 
D2%(PTV) Gy 82.4± 0.1 83.5 ± 0.1 83.2 ± 0.1 83.1 ± 0.0 
D50%(PTV) Gy 79.6 ± 0.4 79.8 ± 0.3 79.8 ± 0.3 79.4 ± 0.4 
V95%(PTV) % 95.1 ± 2.2 94.4 ± 2.4 96.1 ± 2.2 95.4 ± 2.5 
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However no major differences were observed between the techniques. For the target 
volume, the unflattened beams offered comparable dosimetric coverage as compared 
to flattened beams.  
5.1.1 Dose Distributions 
Figure 5.2 shows CT images with isodose lines for the first prostate patient. All the 
beams in figure 5.2 are 10 MV photons. For each patient, plans have been produced 
for IMRT and VMAT with and without FF. The image a) and b) show IMRT plans with 
flattened and unflattened beams, respectively; while c) and d) show VMAT plans with 
flattened and unflattened beams, respectively. 
 
 
Figure 5.2. Planning CT images with isodose lines for the first prostate patient. Images a and b 
show IMRT plans with flattened and unflattened beams, respectively; while c and d show VMAT 
plans with flattened and unflattened beams, respectively. Isodose lines represent planned 
doses of 78 Gy (red), 55 Gy (green), 30 Gy (blue) and 20 Gy (dark blue). 
Apparently, the plans developed with flattened and unflattened beams look very similar, 
for this patient. However, there is a slightly difference, in the volume of the the 20 Gy 
isodose line (dark blue) that seems to be higher for IMRT plans, the isodose line tends 
to be slightly closer to the surface in IMRT plans (a and b) than in VMAT plans (c and 
d). 
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Figure 5.3 shows the comparison of dose distributions for the three prostate patients. 
For each patient VMAT plans are shown: with flattened and unflattened beams. 
 
Figure 5.3. Planning CT images with isodose lines for three patients. Images a, b and c show 
VMAT plans with flattened 10MV beams while d, e and f show plans with unflattened beams. 
Isodose lines represent planned doses of 78 Gy (red), 55 Gy (green), 30 Gy (blue) and 20 Gy 
(dark blue). 
 
5.2 Pareto Fronts 
Pareto fronts were successfully sampled for all cases. As in the study of Ottosson et 
al.31 the results demonstrate that the sampled Pareto fronts follow the definition of the 
Pareto concept, i.e. no solution simultaneously improving, or deteriorating, both 
parameters was found.  
Plans belonging to the same technique (IMRT FF, IMRT FFF, VMAT FF, VMAT FFF) 
constitute the pareto front, enabling comparison of techniques rather than plan to plan. 
The Pareto fronts generated with the four different techniques for case 1 are plotted 
in the same diagram, Figure 5.4. 
The solid line in figure 5.4 is marking the 5% loss of target coverage. 
a b 
d 
 
c 
e f 
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Figure 5.4. Pareto optimal fronts for the first prostate case (191 plans), for IMRT with FF (red 
circles), IMRT without FF (blue squares), VMAT with FF (green diamonds) and VMAT without 
FF (black triangles). 
  
The IMRT FFF front is situated below and to the left of the other fronts indicating that 
this technique exhibit a better combination of target coverage and less dose to the 
rectum, compared to the others. 
The IMRT fronts starts with almost the same target coverage, but the loss of coverage 
is slightly faster for the IMRT FF. The same happens for the VMAT fronts, however 
starting with higher under dosage. Comparing these two fronts the decrease in 
coverage of the VMAT FF front is much faster than the VMAT FFF front. 
For the IMRT fronts the D10% of the rectum is about 66Gy for the 5% loss of target 
coverage while for the VMAT fronts for the same loss of target coverage the D10% is 
about 1.5Gy higher. 
Note that the x axis in figure 5.4 goes up to 12%.  
After the import of the DVHs in MATLAB and plot all the results from the dose 
distributions of the plans from the first patient, it was noticed that most of them are non 
pareto optimal plans. The fronts were created with less number of plans, and no major 
differences have been observed in the fronts, as shown in figure 5.5. The minor 
difference is that IMRT FFF front reaches the 5% loss of target coverage slightly before 
the IMRT FF front. 
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Figure 5.5. Pareto optimal fronts generated for the first prostate case (88 plans), for IMRT with 
FF (red circles), IMRT without FF (blue squares), VMAT with FF (green diamonds) and VMAT 
without FF (black triangles). 
 
The Pareto fronts generated with the four different techniques for case 2 are plotted 
in figure 5.6. 
For this case the IMRT FF front was situated below and to the left of the other fronts 
indicating that this technique is better compared to the others. 
In this case the IMRT FFF front starts with higher under dosage than IMRT FF, but is 
situated below the VMAT fronts. At 5% loss of target coverage the IMRT optimal fronts, 
differed by about 1 Gy, in favour for IMRT FF. 
Regarding the VMAT technique, virtually no difference was observed between the 
Pareto optimal fronts of VMAT and VMAT FFF. While comparing the IMRT FF front 
with the VMAT fronts at 5% loss of target coverage the difference is about 2.5 Gy, as 
shown in figure 5.6. 
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Figure 5.6. Pareto optimal fronts generated for the second prostate case (76 plans), for IMRT 
with FF (red circles), IMRT without FF (blue squares), VMAT with FF (green diamonds) and 
VMAT without FF (black triangles). 
 
Figure 5.7. Pareto optimal fronts generated for the third prostate case (75 plans), for IMRT with 
FF (red circles), IMRT without FF (blue squares), VMAT with FF (green diamonds) and VMAT 
without FF (black triangles). 
For the third case, the fronts laid virtually on top of each other, even if the IMRT FF 
front starts with better target coverage, the difference between the fronts is 
insignificant. 
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By not changing any cost function parameter, except for the rectum used for the fronts, 
and by rejecting plans where the doses to the PTV were compromised, the dose to 
these OAR were consistent for all the techniques and all plans generated, as shown in 
figure 5.7 
5.2.1 Plan comparison 
From the analyses of the Pareto optimal fronts, can be observed that PTV coverage is 
deteriorated with the decrease of the D10% of the rectum.  
For the first and the second cases, IMRT plans appears to be favorable compared with 
the VMAT plans, while for the third case, no significant difference was observed. All the 
techniques performed considerably better for case 2 compared to case 1 and 3. 
All the plans generated had to be sorted to present a Pareto front. This required a large 
number of plans made by varying the EUD maximum for the rectum in smaller steps. 
For the first patient with 191 plans, a huge number of non Pareto optimal plans were 
generated. This could be a result of the way the TPS works. In the first stage the 
optimized fluence maps are created and the dose distribution is calculated with a finite 
size pencil beam algorithm. The optimizer stops automatically when it could not 
improve one objective without deteriorating at least one of the others, i. e., when the 
system found a Pareto optimal plan. But in the second stage, the sequencer tries to 
rebuild these fluence maps by optimizing the number and shape of the segments for 
each beam, and may not always reach a Pareto optimal plan. Decreasing the Monte 
Carlo variance, i. e., increasing the number of histories, may help the system to find a 
better solution but this could increase the planning time and the plans can become 
more complex and difficult to be delivered. 
 
5.3 Treatment time, MU requirements and Segments  
 
 Treatment time 
The treatment time to deliver a single fraction was measured from the start of the first 
beam to the end of the last beam, for IMRT plans; and from the start of the 360º arc to 
the end.  
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Table 5.2 The average time (min), to deliver the initial plans produced for each patient, the 
average of monitor units per fraction required for the same prescription, and the average of the 
total number of segments (seg) of flattened/unflattened for the different techniques 
 
For the first patient, the measured treatment time of the initial plans was about 8 
minutes for IMRT FF.  By the use of IMRT FFF the treatment time was reduced by 25% 
for IMRT FFF (about 6 minutes) and decreased even further for both VMAT 
techniques. 
For the second case the decrease in the treatment time is similar. The measured time 
of the initial plans was about 7.25 minutes for IMRT FF, and without FFF the treatment 
time was reduced by 22%, decreasing even further for VMAT. 
For the third patient the decrease in the treatment time was about 24% between the 
IMRT FF and the IMRT FFF. As for the other cases the VMAT treatment time was even 
lower. 
Comparing the two techniques, IMRT and VMAT with unflattened beams, the decrease 
in the treatment time is about 1.8 times lower in favor for VMAT. 
For the VMAT plans the treatment time increased by a factor of 28%, 23% and 22%, 
for case 1, case 2 and case 3, respectively. This fact was may be due to the huge 
increase in the number of monitor units for the VMAT FFF plans. 
 
 Monitor Units 
The average of MUs for the prostate cases treatment plans, both for IMRT and VMAT, 
with and without flattening filter are listed in table 5.2. 
For the three prostate cases, the lowest numbers of MUs were observed for IMRT FF 
with a mean value of 283, 309 and 291 MUs, respectively. For VMAT FFF the highest 
numbers of MUs were observed for the case 2 with a mean value of 547 MUs. In 
general the number of MUs was always higher for the VMAT FFF technique. 
   T [min:sec]  MU  Seg 
   IMRT VMAT  IMRT VMAT  IMRT VMAT 
Prostate 1  07:49/ 06:15 02:29/ 03:10  283.2/ 321.4 395.2/ 434.5  57/ 58 96/ 96 
Prostate 2  07:16/ 05:58 03:14/ 03:58  308.7/ 362.4 483.1/ 546.6  55/ 48 108/ 108 
Prostate 3  07:34/ 06:05 02:43/ 03:19  291.4/ 324.7 451.2/ 496.1  53 /51 108 /108 
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Although, the number of MU tends to be higher for IMRT FFF, VMAT FF and VMAT 
FFF, the use of these techniques lead to an increase of time efficiency compared to 
IMRT FF. 
The results presented are consistent with Wang et al97. that recently reported that the 
number of MUs for FFF mode could be 10-16% higher for prostate cases. In this case 
the increase of the MUs for the IMRT FFF plans was about 13%, 15% and 10% for 
case 1, 2 and 3, respectively. Regarding the VMAT plans the increase for the three 
prostate cases were about 9%, 12% and 9%, respectively.  
This is an expected consequence of unflattened delivery because of the shape of the 
beam profile; delivering any dose off-axis will require the beam to be on for a longer 
period of time. 
 
 Segments 
Table 5.2 compares the number of segments required to deliver the same dose 
distribution with two techniques: IMRT with FF and FFF and VMAT with and without FF. 
Taking the ratio of (unflattened IMRT/conventional IMRT) for each of the three prostate 
cases, the average for the number of segments required was 1.02, 0.87 and 0.96, for 
case 1, case 2 and case 3, respectively. For the VMAT plans no difference in the 
average number of segments was noticed.  
In most cases, the number of segments needed for an unflattened beam is slightly 
more than that for the corresponding flattened beam. In this case this assumption was 
not verified. 
 
5.4 CI and HI 
The values of CI and HI for the three prostate treatment plans were computed and 
tabulated in table 5.3. 
In general the conformation was better for the VMAT plans and was worse for the 
IMRT FF.  
To quantify dose uniformity in the PTV, it was calculated for each plan the homogeneity 
index. An HI of zero indicates that the dose distribution is almost homogeneous. 
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For the three cases, no significant differences were found between treatment plans 
with flattened and those using unflattened beams. Nevertheless better homogeneity 
indices were found for the IMRT FF plans with better homogeneous dose distribution. 
 
Table 5.3 Comparison of the CI and HI in the IMRT and VMAT plans with and without FF for the 
three prostate cases 
 Conformity Index 
 IMRT FF IMRT FFF VMAT FF VMAT FFF 
Prostate 1 0.81 ± 0.02 0.81 ± 0.02 0.83 ± 0.01 0.82 ± 0.02 
Prostate 2 0.86 ± 0.01 0.86 ± 0.01 0.88 ± 0.01 0.86 ± 0.01 
Prostate 3 0.85 ± 0.02 0.86 ± 0.02 0.88 ± 0.01 0.88 ± 0.01 
 Homogeneity Index 
 IMRT FF IMRT FFF VMAT FF VMAT FFF 
Prostate 1 0.10 ± 0.02 0.11 ± 0.01 0.13 ± 0.01 0.13 ± 0.01 
Prostate 2 0.12 ± 0.02 0.14 ± 0.02 0.14 ± 0.01 0.14 ± 0.01 
Prostate 3 0.13 ± 0.02 0.15 ± 0.02 0.13 ± 0.02 0.13 ± 0.02 
 
5.5 Gamma evaluation  
The agreement between the measurements, performed with the Delta 4 phantom, and 
calculations made in MonacoTM were compared for the three prostate cases, for the 
four initial plans of each technique. The results of the gamma evaluation are listed in 
table 5.4. 
 
Table 5.4 Gamma index evaluation: results of the comparison between measured (Delta4) and 
calculated (Monaco
TM
) 
 
The gamma value averaged over all measured pixels was calculated. This value gives 
information about how close the calculation is to the measurement averaged over the 
 -mean  -max  ≤ 1 
  
IMRT 
FF 
IMRT 
FFF 
VMAT 
FF 
VMAT 
FFF 
 IMRT 
FF 
IMRT 
FFF 
VMAT 
FF 
VMAT 
FFF 
 IMRT 
FF 
IMRT 
FFF 
VMAT 
FF 
VMAT 
FFF 
Patient 1 0.21 0.22 0.22 0.43  1.21 1.08 0.98 1.82  99.6 99.6 100 90.2 
Patient 2 0.25 0.28 0.22 0.32  1.04 1.65 0.89 1.20  99.8 97.7 100 99.1 
Patient 3 0.23 0.30 0.24 0.33  0.96 1.50 0.90 1.45  100 97.2 100 95.9 
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area of measurement. The lower the value the better the agreement.  The average 
number of pixels with γ≤1, and the maximum γ value expressed as the 1st percentile 
(γ1%) was also calculated. 
For the three patients the four initial plans were measured with the Delta 4 phantom 
and analyzed with Scandidos software. The gamma analyzes was performed. 
Averaged over these 3 patients, four planes per patient, one per each technique, the 
mean gamma values for IMRT FF, IMRT FFF, VMAT FF and VMAT FFF, were 0.23, 
0.27, 0.23 and 0.36, respectively. These results showed high agreement with 
calculated values. For the same plans, the percentage of plans with a gamma smaller 
than 1 was 99.8%, 98.2%, 100% and 95.1%, respectively. 
For the prostate 1, the γ-mean for VMAT FF plan was 0.43, filling the acceptability 
criteria, but in average the number of pixels exceeding a gamma of 1.0 was 9.78%. 
This is an acceptable value; however other verification tools such as angle distribution, 
dose difference map, profiles are needed for further evaluation. A more detailed 
investigation concerning the dose calculation accuracy is beyond the scope of this 
study and will be studied later on. 
In general techniques with flattened beams showed a better agreement between 
measurements and calculations. 
Due to the non-uniform shape of the flattening filter, the beam energy distribution will 
vary with the off-axis distance. In theory the removal of the flattening filter facilitates the 
dose calculation and might improve the dose calculation accuracy of advanced 
algorithms.17 However this was not observed in this study. 
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6 Conclusions and Future work 
 
This study contributed to a professional enrichment in the treatment planning field and 
will help in the implementation of flattening filter free Linacs at the Portuguese 
Radiotherapy departments. 
When a new technique is being introduced, in this case a flattening filter free beam 
from a conventional accelerator, it is needed to explore the properties and the potential 
benefits and drawbacks of using unflattened beams. 
The dosimetric properties of the unflattened beams were studied and the feasibility of 
developing clinically acceptable treatment plans using unflattened beams, and 
compare them with typical plans developed with flattened beams was the aim of this 
study. 
The results show that it was possible to develop clinically acceptable plans for IMRT 
and VMAT, with flattened and unflattened beams. In terms of dose distribution, 
treatment plans with flattened and unflattened beams were of similar plan quality. The 
same median dose was achieved for all modalities, which is a prerequisite to achieve 
similar and comparable clinical conditions with respect to tumor control. 
Due to different planning philosophies and/or poor statistics, conventional planning 
studies based on DVHs comparison often lead to inconclusive results. It is believed 
that the use of Pareto optimal fronts will reduce these influences. Therefore the 
feasibility of Pareto optimal fronts to compare the two delivery techniques has been 
evaluated. 
The results indicate that the use of Pareto fronts is a feasible approach to compare 
different techniques and technologies for advanced radiotherapy. 
Comparing Pareto fronts instead of single plans gives a clearer view of the whole 
picture. The whole range of doses to an OAR can be assessed at the same time 
and correlated with the target coverage. If two single plans are compared the 
position on the Pareto front could be missed or the selected plan might not be 
Pareto optimal. 
The Pareto optimal fronts give also information that is not accessible in a DVH. This 
can be seen, for the first and the third patient. For the first patient the IMRT fronts show 
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that is possible to spare the rectum without losing target coverage, the same happens 
in the second case for the VMAT techniques.  
For the cases studied the IMRT fronts were generally found to be more favorable. 
Nevertheless one should not set aside the possibility of using VMAT plans, as there 
might be cases benefiting from this technique, as already reported in several 
papers.55,97-100 
In order to perform the Pareto fronts to compare the four techniques, equivalent 
treatment plans were performed. To be equivalent to a full arc VMAT plan, an IMRT 
plan with nine beams have been created, however this is not the number of beams 
used in clinical routine. This amount of beams give more degrees of freedom to the 
system and let the system create a more conformal dose distribution; however the 
treatment time increased largely and the low doses must be evaluated. 
Another application for the Pareto fronts is to use them to aid treatment planning.  It 
would be advantageous if patients could be selected prior to treatment planning, based 
on some criteria. The selection criteria could include patient size and tumor location, 
tumor size and proximity to other structures, etc. However, this is beyond the scope of 
this work and could be a subject of future investigations. 
This study shows that for IMRT without flattening filter, the treatment delivery time 
reduces by about 24%, and even further for VMAT techniques with and without FF. 
However, total MUs are much larger for FFF delivery for all the cases due to the non-
flatness of the dose profile. Accordingly with Wang et al. the number of MUs for 
unflattened beams could be 10-16% higher for prostate cases. This study reports an 
increase in the number of monitor units of 9-15% for unflattened beams compared to 
conventional IMRT and VMAT beams. With different optimization algorithms and 
segmentation algorithms, adjusted for unflattened beams the number of monitor units 
of the unflattened/flattened IMRT/VMAT plans may reduce, and consequently the 
treatment delivery times may reduce even further. 
The TPS MonacoTM has been commissioned for unflattened beams. The initial 
treatment plans performed for each patient and for each technique were measured and 
compared with calculations, by gamma analyses. The results of the mean gamma 
value, the average number of pixels with γ≤1, and the maximum γ value expressed as 
the 1st percentile (γ1%) showed a very good agreement between measurements and 
calculations. 
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In theory, the dosimetric characteristic of unflattened beams facilitates dose calculation 
and might improve the dose calculation accuracy of advanced algorithms. The 
calculation accuracy of the unflattened beams was beyond the scope of this study and 
will be subject of future investigations. 
 
6.1 Study limitations 
This study has been performed with a non-clinical version of MonacoTM. The TPS 
sequencer was able to deal with unflattened beams and to create plans with similar 
plan quality comparing with conventional IMRT and VMAT plans. Nevertheless it was 
noticed that some improvements should be done in the optimization and segmentation 
algorithms, in order to give better results for unflattened beams.  
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